<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712500</url>
  </required_header>
  <id_info>
    <org_study_id>AND017-CN-101</org_study_id>
    <nct_id>NCT04712500</nct_id>
  </id_info>
  <brief_title>A Food-Effect Study of AND017 in Healthy Participants</brief_title>
  <official_title>A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period Crossover Study in Healthy Non-Elderly Chinese Subjects to Evaluate the Food Effect on the Pharmacokinetics of AND017 Following Oral Single-Dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kind Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kind Pharmaceuticals LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase I study is to evaluate the food effect on the PKs of AND017&#xD;
      following oral single-dose administration in healthy non-elderly Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, open-label, two-sequence, two-period crossover study in&#xD;
      healthy non-elderly Chinese subjects to evaluate the food effect on the pharmacokinetics, as&#xD;
      well as PD and safety of AND017 following oral single-dose administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Actual">August 21, 2020</completion_date>
  <primary_completion_date type="Actual">August 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 6, 0-72 hours post-dose</time_frame>
    <description>Maximum Observed Plasma Concentration for AND017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Day 1 and Day 6, 0-72 hours post-dose</time_frame>
    <description>Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for AND017</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AND017: Fasted - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AND017: Fed - Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AND017</intervention_name>
    <description>AND017 oral capsule</description>
    <arm_group_label>AND017: Fasted - Fed</arm_group_label>
    <arm_group_label>AND017: Fed - Fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI between 19.0~26.0 kg/m2 (both inclusive); Body weight ≥50 kg for male, and ≥45 kg&#xD;
             for female.&#xD;
&#xD;
          2. Healthy participants having no clinical significant abnormalities of examinations&#xD;
             during screening period and at the time of informed consent&#xD;
&#xD;
          3. Have no pregnancy plan in the next six months and are willing to take effective&#xD;
             contraceptive methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic constitution or has a history of allergy to AND017 capsule and its excipient;&#xD;
&#xD;
          2. Subjects with low blood pressure or a risk of low blood pressure: systolic pressure&#xD;
             &lt;90 mmHg, diastolic pressure&lt;60 mmHg.&#xD;
&#xD;
          3. Subjects with difficulty in venous blood sampling;&#xD;
&#xD;
          4. Subjects with a history of drug abuse within the past five years or who have abused&#xD;
             drug within the past three months before screening;&#xD;
&#xD;
          5. Subjects smoking more than five cigarettes a day or nicotine dependent within the past&#xD;
             three months before screening;&#xD;
&#xD;
          6. Subjects drinking alcohol more than 14 U/week within the past six months or used any&#xD;
             alcohol products in two days pre-dose;&#xD;
&#xD;
          7. Subjects that have received any medication within the past 4 weeks pre-dose;&#xD;
&#xD;
          8. Subjects that have taken food or drink that has the potential to induce or inhibit&#xD;
             drug metabolizing enzymes in the liver within one-week pre-dose;&#xD;
&#xD;
          9. Subjects that have taken any food or drink that contains or can be metabolized to&#xD;
             caffeine or xanthine from 48 hours pre-dose to the last PK or PD blood sampling;&#xD;
&#xD;
         10. Subjects with diseases or factors of clinical abnormalities that need to be excluded,&#xD;
             including but not limited to the nervous system, cardiovascular system, kidney, liver,&#xD;
             gastrointestinal, respiratory system, metabolism, and skeletal system diseases, or&#xD;
             other factors that may affect drug absorption, distribution, metabolism and excretion;&#xD;
&#xD;
         11. Subjects that have used HIF-PHIs within the past one year;&#xD;
&#xD;
         12. Subjects positive in HIV-Ab, HBsAg or HBeAg, or HCV-Ab, TP-Ab;&#xD;
&#xD;
         13. Subjects that have participated in any other clinical trials within the past three&#xD;
             months pre-dose in the study;&#xD;
&#xD;
         14. Female subjects of childbearing age who are pregnant, lactating, or planning&#xD;
             pregnancy; or have a positive in pregnancy test during the study;&#xD;
&#xD;
         15. Subjects with a history of blood donation or had a blood loss more than 400 mL within&#xD;
             three months before screening;&#xD;
&#xD;
         16. Subjects that have special requirements on diet and cannot follow the dietary program&#xD;
             indicated in the study;&#xD;
&#xD;
         17. Subjects that are unable to comply with research requirements or with any factors are&#xD;
             considered not suitable for participating in the study according to the opinion of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusha Zhu, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kind Pharmaceuticals LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

